Pacira presents evidence real-world evidence from IGOR

Pacira (PCRX) BioSciences presented real-world evidence from its Innovations in Genicular Outcomes Registry, IGOR, a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstrated that Exparel was associated with improvements in pain, opioid use, function, and length of stay after receiving EXPAREL following total knee arthroplasty as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated that cryoneurolysis treatment with iovera was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4-6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons, AAOS, 2026 Annual Meeting taking place March 2-6 in New Orleans, Louisiana.